Case Study

The miracle balm of Gilead (B)

6 pages
April 2015
Reference: IMD-7-1620

The second part of this case series describes the protests about the cost of Sovaldi which continued throughout the summer of 2014, not only in emerging markets but also in developed countries. In PR terms, Gilead was being painted less as a marvelous creator of a miracle drug and more as an arbiter of who might live or die from hepatitis C, based entirely on whether they could afford it or not. In September 2014, Gilead surprised everyone.

Keywords
Biotechnology, Healthcare, Healthcare Costs, Health Insurance, Pricing, Non-Governmental Organization, Pressure Group, Competitor Analysis, Epidemiology, Medecine
Settings
World/global, United States of America
Gilead Sciences, Manufacturing, Biotechnology, Healthcare, Pharmaceuticals
2014-2015
Type
Published Sources
Copyright
© 2015
Available Languages
English
Case clearing houses
Contact

Research Information & Knowledge Hub for additional information on IMD publications

Discover our latest research
IMD's faculty and research teams publish articles, case studies, books and reports on a wide range of topics